Haematologica (Jan 2020)
A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas
- Paolo Strati,
- Loretta J. Nastoupil,
- Richard E Davis,
- Luis E. Fayad,
- Nathan Fowler,
- Fredrick B. Hagemeister,
- Larry Kwak,
- Yasuhiro Oki,
- Michael Wang,
- Jason Westin,
- Charnelle E. Ruben,
- Emily T. Wesson,
- Richard Piekarz,
- Michelle A. Fanale,
- Hun Ju Lee
Affiliations
- Paolo Strati
- Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX
- Loretta J. Nastoupil
- Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
- Richard E Davis
- Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
- Luis E. Fayad
- Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
- Nathan Fowler
- Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
- Fredrick B. Hagemeister
- Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
- Larry Kwak
- Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
- Yasuhiro Oki
- Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
- Michael Wang
- Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
- Jason Westin
- Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
- Charnelle E. Ruben
- Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
- Emily T. Wesson
- Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
- Richard Piekarz
- Investigational Drug Branch of CTEP, National Cancer Institute, Bethesda, MD, USA
- Michelle A. Fanale
- Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
- Hun Ju Lee
- Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
- DOI
- https://doi.org/10.3324/haematol.2019.220012
- Journal volume & issue
-
Vol. 105,
no. 1
Abstract
No abstracts available.
